Page 80 - ESHRE2019
P. 80
Clinical implications
Evaluating hESC diversity will support safer clinical implementation
Clinical implications: strategies to overcome tumorigenicity
• Terminal differentiation or complete elimination of residual pluripotent stem cells from culture
• Interfering with tumour-progression genes to prevent tumour formation from the residual pluripotent cells
• Further research on the tumorigenicity of hPSCs, its sources and its consequences will ultimately lead to safer clinical applications
78
75
